Gear Up for Alcon (ALC) Q4 Earnings: Wall Street Estimates for Key Metrics

In its upcoming report, Alcon (ALC) is predicted by Wall Street analysts to post quarterly earnings of $0.79 per share, reflecting an increase of 9.7% compared to the same period last year. Revenues are forecasted to be $2.71 billion, representing a year-over-year increase of 9.3%.The current level reflects an upward revision of 1.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.With that in mind, let's delve into the average projections of some Alcon metrics that are commonly tracked and projected by analysts on Wall Street.Analysts expect 'Net Sales- Total Surgical- Equipment/other' to come in at $277.54 million. The estimate indicates a change of +21.2% from the prior-year quarter.Analysts' assessment points toward 'Net Sales- Total Surgical- Implantables' reaching $482.10 million. The estimate points to a change of +5.7% from the year-ago quarter.According to the collective judgment of analysts, 'Net Sales- Total Surgical' should come in at $1.56 billion. The estimate indicates a year-over-year change of +9.3%.Analysts predict that the 'Net Sales- Total Vision care' will reach $1.15 billion. The estimate indicates a year-over-year change of +9.1%.It is projected by analysts that the 'Net Sales- Total Surgical- Consumables' will reach $796.13 million. The estimate indicates a year-over-year change of +7.9%.The consensus estimate for 'Net Sales- Total Vision Care- Contact lenses' stands at $687.14 million. The estimate points to a change of +7.7% from the year-ago quarter.The combined assessment of analysts suggests that 'Net Sales- Total Vision Care- Ocular health' will likely reach $462.70 million. The estimate indicates a change of +11.2% from the prior-year quarter.The average prediction of analysts places 'Net Sales and other revenues- Other revenues' at $26.18 million. The estimate suggests a change of +4.7% year over year. View all Key Company Metrics for Alcon here>>> Over the past month, Alcon shares have recorded returns of +0.8% versus the Zacks S&P 500 composite's -0.8% change. Based on its Zacks Rank #3 (Hold), ALC will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks